Toronto Star
🏢 Torstar
📍 ON
May 18, 2026
· 2 min read
AI Analyzed
○ Unverifiable
View full audit trail →
Supreme Court rejects appeals from drug manufacturers over Medicare price negotiations - thestar.com
Original article ↗ 🔒 Paywalled source — limited preview availableB.I.A.S. ANALYSIS
CENTER
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3)
0.00 · CENTER
ML v2 (DistilBERT)
0.245 · RIGHT
Ensemble
0.122 · CENTER
🏦 Source Intelligence
Rolling outlet bias
CENTER
avg -0.043
8,007 articles tracked
7-day bias trend
LcenterR
V.E.R.I.F.Y. has fact-checked this article.
Subscribe to see claim-by-claim verdicts and reasoning.
Subscribe to see claim-by-claim verdicts and reasoning.
Article Excerpt
The U.S. Supreme Court has declined to hear challenges from several drug manufacturers aimed at blocking or limiting Medicare's authority to negotiate prices for certain drugs.
In a brief order issued on Monday, the court denied the requests for review filed by AbbVie, Eli Lilly and Merck, among others. The companies had argued that allowing Medicare to negotiate directly with pharmaceutical firms could lead to higher costs for taxpayers and undermine competition in the industry.
Medicare's Price Negotiation Program, which was established under the Affordable Care Act (ACA) in 2010 but only …
Read full article at Toronto Star ↗
How we scored this article
WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.
Analyzed by
B.I.A.S.
V.E.R.I.F.Y.
L.O.C.A.L.
quick v1 + full
Jun 5, 2026